Bicara Therapeutics (BCAX) Insider Exercise and Proposed Sale of 33,807 Shares

Rhea-AI Filing Summary

Bicara Therapeutics (BCAX) Form 144 reports a proposed sale of 33,807 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $395,879.97, representing part of the issuer's outstanding 54,562,841 shares. The shares were acquired and will be sold on 09/29/2025 upon exercise of stock options, with payment in cash. The filing also discloses 10b5-1 plan sales by Lara Meisner of 15,829 shares on 09/15/2025 for gross proceeds of $181,893.96. The filer attests there is no undisclosed material adverse information and includes standard Rule 144 and 10b5-1 representations.

Positive

• Transparent disclosure of the option exercise, proposed sale, broker, quantities and prices
• Use of a major broker (Morgan Stanley Smith Barney LLC) for execution, indicating standard market channels
• Attestation that no undisclosed material adverse information exists and inclusion of 10b5-1 details

Negative

• Insider selling activity: Proposed sale of 33,807 shares and a recent 09/15/2025 sale of 15,829 shares may be monitored by investors
• Potential short-term increase in free float from option exercise followed by immediate sale (33,807 shares)

Insights

Securities Analyst

TL;DR: Insider-originated option exercise and planned sale increases share supply but appears routine and disclosed under Rule 144.

The transaction details show a non-cash acquisition via stock option exercise on the sale date, with an immediate proposed sale through a major broker. The size—33,807 shares versus 54.56 million shares outstanding—is small in absolute and relative terms, suggesting limited direct market impact. Prior 10b5-1 sales by the same account within the month are disclosed, indicating an established trading plan or routine liquidity activity rather than an ad hoc block sale.

Corporate Governance Expert

TL;DR: The filing is compliant and transparent but highlights insider selling activity that investors may note.

The filer provides required attestation about lack of undisclosed material information and references Rule 10b5-1 where applicable. The disclosure of both the option exercise and recent 10b5-1 sales demonstrates procedural compliance. While insider sales are disclosed properly, governance watchers typically track patterns of repeated sales; the record here shows a recent sale on 09/15/2025 and the proposed sale on 09/29/2025, which may warrant monitoring for trends.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	33807	395879.97	54562841	09/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/29/2025	Exercise of Stock Options	Issuer			33807	09/29/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for LARA MEISNER 116 Huntington Ave Suite 703 Boston MA 02116	Common	09/15/2025	15829	181893.96

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares of BCAX are proposed to be sold under this Form 144?

The filing reports a proposed sale of 33,807 common shares with an aggregate market value of $395,879.97.

When were the shares acquired and how were they acquired?

The shares were acquired on 09/29/2025 by exercise of stock options and the payment method is listed as cash.

Who is the broker handling the sale for BCAX shares?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Did the filer sell any BCAX shares in the past three months?

Yes. The filing discloses a 10b5-1 sale by Lara Meisner of 15,829 shares on 09/15/2025 for gross proceeds of $181,893.96.

How many BCAX shares are outstanding according to the filing?

The filing lists 54,562,841 shares outstanding.